BioSpace News Archive

At the 2020 AACC Annual Scientific Meeting & Clinical Lab Expo, a series of late-breaking sessions will delve into the newest research on the rapidly evolving COVID-19 pandemic.

Zynx Health® today announced that it has published a new, publicly available review of vaccine administration guidelines specific to COVID-19 vaccines, including Pfizer/BioNTech BNT162b2, the COVID-19 vaccine co-developed by Pfizer and BioNTech, following its emergency use approval by the U.S. Food and Drug Administration (FDA).

After nearly 10 months of managing an illness that has killed nearly 300,000 and sickened more than 15 million Americans, Northwell Health today took a major step toward the end of the COVID-19 pandemic. This press release features multimedia. View the full release here: https://www

Eucrates Biomedical Acquisition Corp. (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, today announced that holders of the units sold in the Company’s initial

St. Joseph’s Children’s Hospital has enhanced its services for pediatric and adult congenital heart defect patients with the addition of a pediatric cardiologist with specialized training in congenital cardiac magnetic resonance imaging, Ryan Boggs, M.D.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced top-line results from the landmark DREAM-HF Phase 3 randomized controlled trial of its allogeneic cell therapy rexlemestrocel-L (REVASCOR ® ) in 537 patients with advanced chronic heart failure 1 . Over a mean 30 months of follow-up, patients with advanced chronic heart failure who received a single endomyocardial trea

Two skin screening clinics opened in November 2020, with more than 800 assessments on close to 500 patients completed to date using MedX’s DermSecure® platform

Boston Scientific Corporation announced that a stipulation of dismissal has been filed in the Nevro Corporation patent infringement case against Boston Scientific in the United States District Court for the Northern District of California.

Atlanta Oral & Facial Surgery and Bay Area Oral Surgery Management, both well-respected and nationally recognized oral surgery groups, announced that they have entered into a strategic partnership with Blue Sea Capital, a leading growth-oriented private equity firm, to form Beacon Oral Specialists and to position AOFS and BAOSM for continued expansion.

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced the pricing of its previously announced underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $20.00 per share